EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Research Progress of Platinum‐Based Anticancer Drugs in Combination with Macrocyclic Drug Delivery System

Li Yang, Pengmin Shi, Bo Yang, Jing Yang, Jian Zhao iD, Chuanzhu Gao

Macromolecular Rapid Communications · 2026-08 · 47 (16)

DOI: 10.1002/marc.70355 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Macromolecular Rapid Communications, online erschienen am 10.07.2026. Verfasst von Li Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, P. R. China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Macrocyclic Compounds, Drug Delivery Systems, Neoplasms. Die Arbeit nennt 85 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Platinum‐based anticancer drugs represent a cornerstone of clinical cancer chemotherapy, yet their clinical application is severely limited by inherent drug resistance and systemic toxic side effects. Macrocyclic compounds, such as cucurbiturils, cyclodextrins, crown ethers, calixarenes and pillararenes, possess unique cavity structures and excellent molecular recognition capabilities, offering promising strategies for optimizing the chemotherapeutic efficacy of platinum‐based drugs. This review summarizes the latest research progress in supramolecular systems constructed from macrocyclic compounds and platinum‐based drugs via host–guest interactions. It focuses on the roles of such supramolecular complexes in improving drug solubility, stability, tumor targeting, and controlled release performance, as well as their potential to overcome drug resistance and reduce toxicity. Furthermore, the applications of functionalized macrocyclic compounds in intelligent drug delivery and combination therapy are discussed, and future directions, including novel macrocyclic carriers, multifunctional nanoplatforms, and combination with immunotherapy and gene therapy, are prospected. This review aims to provide useful references for the development of precise and personalized applications of platinum‐based drugs in cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsMacrocyclic CompoundsDrug Delivery SystemsNeoplasmsPlatinumOrganoplatinum CompoundsHumansDrug Carriers

Stichwörter der Autor:innen

antitumordrug delivery systemmacrocyclic compoundsplatinum‐based anticancer drugstargeted delivery

Substanzen

Antineoplastic AgentsMacrocyclic CompoundsDrug CarriersPlatinumOrganoplatinum Compounds

Autor:innen und Institutionen

  • Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, P. R. China.
  • School of Chemistry and Chemical Engineering, Southeast University, Nanjing, P. R. China.

ORCID-Profile: Jian Zhao

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Yang, L., Shi, P., Yang, B., Yang, J., Zhao, J., & Gao, C. (2026). Research Progress of Platinum‐Based Anticancer Drugs in Combination with Macrocyclic Drug Delivery System. Macromolecular Rapid Communications, 47(16). https://doi.org/10.1002/marc.70355

Vancouver

Yang L, Shi P, Yang B, Yang J, Zhao J, Gao C. Research Progress of Platinum‐Based Anticancer Drugs in Combination with Macrocyclic Drug Delivery System. Macromolecular Rapid Communications. 2026;47(16). doi:10.1002/marc.70355

BibTeX
@article{Yang2026,
  author = {Yang, Li and Shi, Pengmin and Yang, Bo and Yang, Jing and Zhao, Jian and Gao, Chuanzhu},
  title = {Research Progress of Platinum‐Based Anticancer Drugs in Combination with Macrocyclic Drug Delivery System},
  journal = {Macromolecular Rapid Communications},
  year = {2026},
  volume = {47},
  number = {16},
  doi = {10.1002/marc.70355}
}
Kostenlos starten →